NCT03157128 2026-04-16LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 24 charts 6 FDA
NCT05797246 2026-04-14Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)National Institutes of Health Clinical Center (CC)Phase 2 Active not recruiting21 enrolled
NCT05462717 2026-04-08Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1 Active not recruiting222 enrolled
NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 4 FDA